HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.

AbstractBACKGROUND:
The simultaneous presentation of systemic diffuse large B cell lymphoma (DLBCL) with central nervous system (CNS) disease is not well controlled by either R-CHOP or systemic methotrexate (MTX) alone.
METHODS:
We conducted a pilot trial with 6 patients who were initially diagnosed with systemic DLBCL with CNS involvement. Patients were treated with a systemic MTX plus R-CHOP regimen.
RESULTS:
The overall response rate was 4/6 (66.7%). The CNS response rate and systemic response rate were 4/6 (66.7%) and 5/6 (83.3%), respectively. The median response duration of the 4 patients with complete remission at completion was 25.5 months, and the median survival of all patients was 25.1 months. CNS lesions progressed in all relapsed and refractory patients, while systemic disease progression was observed in 1 patient. No fatal hematologic adverse effects, hepatotoxicity or nephrotoxicity were observed.
CONCLUSIONS:
The dose of systemic MTX (1∼1.5 g/m(2)) or dose intensity (4-week interval in 4 patients) used in this trial was considered insufficient. Therefore, the dose of MTX or interval of each chemotherapy cycle should be modified in future trials to control CNS disease involved with DLBCL.
AuthorsKwai Han Yoo, Ji Yun Lee, Sung Hee Lim, Young Hyeh Ko, Seok Jin Kim, Won Seog Kim
JournalActa haematologica (Acta Haematol) Vol. 133 Issue 2 Pg. 179-82 ( 2015) ISSN: 1421-9662 [Electronic] Switzerland
PMID25323539 (Publication Type: Journal Article)
Copyright© 2014 S. Karger AG, Basel.
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
  • Methotrexate
Topics
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage, adverse effects)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Disease-Free Survival
  • Doxorubicin (administration & dosage, adverse effects)
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, mortality, pathology)
  • Male
  • Methotrexate (administration & dosage, adverse effects)
  • Middle Aged
  • Nervous System Diseases (drug therapy, mortality, pathology)
  • Pilot Projects
  • Prednisone (administration & dosage, adverse effects)
  • Rituximab
  • Survival Rate
  • Time Factors
  • Vincristine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: